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Abstract
Objective: The objective of this selective EBM review is to determine whether or not “Is
cariprazine effective and safe in treating acute mania in bipolar I disorder?”
Study Design: This review is based on three double-blind, randomized controlled trials (RCTs)
published in English, in 2015. These studies compared both the efficacy, safety, and tolerability
of cariprazine in the treatment of acute mania in bipolar I disorder.
Data sources: Three double-blind, placebo-controlled, RCTs published in English, in peerreviewed journals, and found using Medline, Pubmed, and Cochrane Review databases.
Outcomes Measured: The primary efficacy scale used in all studies was the Young Mania
Rating Scale (YMRS) which is a screening tool that objectively and subjectively measures acute
mania items including: irritability, speech, content, disruptive behavior, elevated mood,
increased motor activity, sexual interest, sleep, language-though disorder, appearance, and
insight. Safety was measured through the occurrence of one or more of the following during
treatment as experienced by the patient: extrapyramidal disorder, headache, akathisia,
constipation, nausea, dyspepsia, dizziness, insomnia, vomiting, diarrhea, restlessness, sedation,
vision blurred, mania, pain in extremity, pyrexia, tremor, agitation, or toothache.
Results: All three studies found cariprazine demonstrated efficacy and general tolerability in the
treatment of mania in acute bipolar I disorder compared to placebo (p<0.05). The YMRS
baseline scores compared to week 3 after treatment with carpirazine low dose (3 mg/day) and
high dose (12 mg/day) were significantly lower than the placebo group (p<0.05) in all three
studies. According to all three studies the most common treatment related adverse events were:
akathisia, extrapyramidal symptoms, nausea, and constipation.
Conclusions: The results based on these three studies is the cariprazine is effective and generally
well-tolerated for patients experiencing acute mania in bipolar I disorder. Future study is
warranted to determine the remission rate of manic episodes after treatment with cariprazine for
bipolar I disorder.
Key Words: Cariprazine, bipolar disorder
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Introduction
Bipolar I disorder is a mood disorder causing shifts in mood, energy levels, and ability to
function in daily living that is characterized by both manic and depressive episodes.4,5 These
manic episodes are characterized by decreased need for sleep, flight of ideas, increase in
psychomotor agitation, or excessive involvement of pleasurable activities that have high risk of
consequence for at least 1 week.4,8 Following these manic episodes cycles depressive states of
decreased pleasure, diminished interest, apathy, and decreased appetite.8 Patients diagnosed with
bipolar I disorder have may have continued difficulty in psychosocial functioning with daily
living.5,8 This paper evaluates three randomized controlled studies exploring the efficacy and
safety of cariprazine, a partial dopamine receptor agonist in treating acute mania in bipolar I
disorder.
Bipolar disorder affects 5.7 million American adults, or 2.6% of adults over 18 every
year.6 The typical age of onset is between 20 and 30 years old, although premorbid symptoms are
commonly reported in early adolescence.4,8 The prevalence is equal between men and women,
however men are more prone to manic episodes, while women are susceptible to more
depressive episodes over respective lifetimes.8 The estimated total healthcare cost of bipolar
disorder was $45 billion per year in 1991 (the most recent data). Most of the cost was attributed
to decreased functional capacity and lost work days.7 There is no exact estimate of total
hospitalizations, but in 2002-2003, the diagnosis of bipolar disorder of youth 19 and younger in
office visits was 1,003 for every 100,000.5
The cause of bipolar disorder in currently being studied and is ill-defined. It is believed to
be multifactorial including: hormone alterations of serotonin and dopamine in the brain,
hyperexcitability of neuron potentials, genetic, and environmental.4,5 Genetic predispositions
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play a large role in bipolar I disorder carrying a risk of 80% for monozygotic twins.8 Genome
studies have identified diacylglycerol kinase (DGKH), ankryin G (ANK3), L-type voltage-gated
calcium channel (CACNA1C), and a region on chromosome 16p12 as being pertinent to bipolar
1 disorder.4,8 Environmental factors such as stress, social-behavioral patterns, and increasing
sympathetic nervous activity have been shown to affect the disease process.4 Elevation of
cortisol (through stress) impairing hippocampal events decreased limbic activation and
neurogenesis. In addition, regulation of dopamine in the nucleus accumbens has been associated
with depressive episodes, while over expression of glycogen synthase kinase in glutamate
receptors have been associated with manic episodes.8
The diagnosis of bipolar I disorder is made on the history and physical exam of the
patient with one or more manic episodes (lasting at least 1 week) which cycle with depressive
episodes.4 There is no definitive cure for bipolar I disorder and treatment includes a multimodality approach including medication, cognitive-behavioral therapy, and electroconvulsive
therapy. Acute treatment of manic episodes in bipolar I disorder include: lithium, valproic acid,
and possibly benzodiazepines (with psychotic symptoms).5,8 Second generation anti-psychotics
such as olanzapine, risperidone, and quitepaine have also been shown to be effective.4,8 Current
treatments such as lithium are continually being evaluated because of adverse side effects
including tremor, hypothyroidism, arrhythmias, seizures and blood monitoring every 4-8 weeks.8
Bipolar disorder is a complex, multifactorial disease that involves recurrence and variable
severity of symptoms even with current treatment regimens as listed above. Cariprazine is being
proposed to safely treat acute mania in bipolar I disorder with positive long term effects on
quality life.
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Objective
The objective of this selective EBM review is to determine whether or not carpirazine is
effective and safe in treating acute mania in bipolar I disorder.
Methods
Three double-blind, placebo-controlled, randomized controlled studies were included in
this systematic review. In all three studies the patient population included male and female adults
ages 18 to 65 years old with a diagnosis of bipolar I disorder, mixed or manic type, with or
without psychotic symptoms. These studies used oral cariprazine 3 mg -12 mg per day as the
intervention. Calabrese et al.1 randomly assigned patients to either cariprazine 3-6 mg per day
which was considered low dose or 6-12 mg per day which was considered high dose. Durgam et
al.2 and Sachs et al.3 both initiated patients in the randomized treatment group on cariprazine 1.5
mg per day and doubled the dosing after day 2, continuing up to a maximum dose of 12 mg per
day if tolerability and patient response met safety criteria.
All three studies included a no-drug washout period up to 7 days, a 3-week treatment
phase, and a 2-week safety follow-up. Patients were randomized to either the cariprazine
treatment group or the placebo experimental group. The cariprazine group was compared to the
placebo group in terms of YMRS scores to determine the outcomes of efficacy in treating acute
mania in bipolar I disorder.1,2,3 The adverse events and safety of cariprazine was also measured
using subjective symptoms reported by the patient, vital signs, liver function, metabolic
laboratory data and extrapyramidal symptoms.1,2,3
Data sources include three peer-reviewed journal articles, published in English in 2015.
All articles were researched through Medline, Pubmed, and Cochrane Review databases. These
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articles were chosen based on their clinical relevance to my question and inclusion of POEMS.
Key words searched in Pubmed included “cariprazine” and “bipolar disorder”.
Inclusion criteria for all three studies included male and female patients ages 18-65 years
old with a diagnosis of bipolar I disorder, manic or mixed type, with or without psychotic
symptoms. Additional inclusion criteria included a YMRS score of ≥ 20, a score of ≥ 4 on at
least two items: irritability, speech, content, or aggressive behavior, a Montgomery-Asberg
Depression Rating Scale < 18, and a BMI of 18-40 mg/kg. Exclusion criteria varied slightly
between studies but generally included pregnant women, positive pregnancy test at screening,
substance abuse, additional axis I diagnosis, suicide risk, significant medical conditions
(malignancy, hematologic, endocrine, cardiovascular, respiratory, renal, or hepatic disorders),
current use of psychotropic medication, patients treated with cariprazine within 90 days of
screening, patients who received electroconvulsive therapy within 3 months of screening, or a
history of neuroleptic malignant syndrome.
Statistics reported in all three studies included relative risk reduction (RRR), absolute risk
reduction (ARR), numbers needed to treat (NNT), and p-values. Primary statistical analyses were
performed using mixed-effects model with repeated measures (MMRM), analysis of covariance
model (ANCOVA), and 2-sded 95% confidence intervals (CI).1,2,3 Table 1 below displays the
demographics and characteristics of the three studies.
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Table 1: Demographics & Characteristics of Included Studies
Study

Type

# Pts

Age
(yrs)
18-65
years

Inclusion
Criteria
Age 1865 years
with a
diagnosis
of bipolar
I disorder

Calabrese1 Double
(2015)
blind
RCT

497

Durgam2
(2015)

Double
blind
RCT

236

18-65
years

Age 1865 years
with a
diagnosis
of bipolar
I disorder

Sachs3
(2015)

Double
blind
RCT

312

18-65
years

Age 1865 years
with a
diagnosis
of bipolar
I disorder

Exclusion
Criteria
First
manic
episode,
additional
psychiatric
disorder,
risk of
suicide, or
ECT
within 3
months
First
manic
episode,
additional
psych
disorder,
previous
treatment
within 90
days with
depot
neuroleptic
Axis I
diagnosis
other than
bipolar I,
substance
abuse
within 3
months,
ECT
within 3
months or
cariprazine
within 10
years

W/D

Interventions

127

Cariprazine
low dose 36mg/d or
high dose 612mg/d
orally

88

Cariprazine
3-12mg/d
orally

98

Cariprazine
3-12mg/d
orally
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Outcomes Measured
The three studies measured acute mania signs and symptom improvement using the
Young Mania Rating Scale (YMRS). The YMRS measures irritability, speech, content,
disruptive-aggressive behavior, elevated mood, increased motor activity, sexual interest, sleep,
language-thought process, appearance, and insight through patient report as well as investigator
observation.1,2,3 These YMRS scores were administered at the beginning of the study (baseline),
days 3, 5, 7, 10, 14, and 21.1,2,3 The YMRS scores on day 21 were then compared to baseline
scores in both the placebo and treatment group for efficacy.1,2,3
Treatment adverse events were also measured using patient subjective reports, vital signs,
laboratory parameters, and extrapyramidal symptoms.1,2,3 The treatment adverse events (AE’s)
measured included headache, akathisia, constipation, nausea, dyspepsia, dizziness, insomnia,
vomiting, diarrhea, mania, tremor, and agitation.1,2,3 The vital signs measured in Durgam et al.2
included systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg), pulse (bpm), and
body weight (kg). Calabrese et al.1 and Sachs et al.3 included these vital signs as well as waist
circumference (cm). The laboratory values measured at baseline as well as week 3 included total
cholesterol (mg/dL), LDL (mg/dL), HDL (mg/dL), triglycerides (mg/dL), and glucose (mg/dL)
in Durgam et al.2 Calabrese et al.1 and Sachs et al.3 also included alanine aminotransferase (U/L),
aspartate aminotransferase (U/L), total bilirubin (mg/dL), prolactin (ng/dL), and creatine kinase
(U/L).
Results
All three studies reviewed patients ages 18-65 with a diagnosis of bipolar I disorder
treatment with oral cariprazine 3mg-12mg per day compared to that receiving a placebo. In
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Calabrese et al.1 there was a total of 497 patients enrolled in the study with the studies being
performed at 65 different study centers. A total of 48 patients discontinued the study (9%) due to
adverse events, 25 being the highest in the high dose cariprazine group.1 Patients who were
experiencing their first manic episode, significant suicidal risk, pregnant, diagnosed with an
additional axis I disorder, had a substance disorder, significant medical illness, treated with ECT
within the previous 3 months, or treated with depot neuroleptics within 3 months were excluded
from this study.1 The patients were enrolled in a 6-week study that included a no-drug washout
period for up to 7 days, 3 weeks of double-blind treatment, and 2-week safety follow up.1Patients
were randomly assigned to low dose cariprazine 3-6 mg/day group, high dose cariprazine 6-12
mg/day group, or a placebo.1 The control event rate (CER) was calculated to be 37.5% in the
control group and the experimental event rate (EER) was calculated to be 60.6% in the treatment
group.1 This indicates that 60.6% of the patients receiving cariprazine for treatment of acute
mania in bipolar I disorder had a ≥ 50% reduction in YMRS scores at week 3 of the study
compared to the 37.5% in the control group (placebo). The study revealed a relative risk
reduction (RRR) of 61.6% and an absolute risk reduction (ARR) of 23.1%.1 This indicates that
patients taking cariprazine had a 61.6% lower risk of developing acute mania and an absolute
23.1% decrease in acute mania rates compared to the placebo. The number needed to treat
(NNT) was calculated to be 5 (CI 95%), so for every 5 patients taking cariprazine, 1 patient will
have a >50% reduction in acute mania in bipolar I disorder.1
In Sachs et al.2 there was a total of 312 patients enrolled with the studies being performed
at 38 approved study centers. A total of 98 patients discontinued the study, the majority being
withdrawal of consent (16.5%) and patients in the placebo group with an insufficient therapeutic
response (10.4%).2 Patients who were pregnant, had substance abuse disorder, additional axis I
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diagnosis, had suicide risk, had another significant medical condition, had been treated with
clozapine within the last 10 years, or received ECT/depot neuroleptic drugs within the last 3
months were excluded from the study.2 The study included a 3-week, double-blind evaluation of
patients randomized to either cariprazine 3-12 mg/day (based on tolerability) or placebo to treat
acute mania.2 The CER was calculated to be 44.1% for the control group and the EER was
calculated to be 58.9% in the treatment group.2 This indicates that 58.9% of the patients
receiving cariprazine for treatment of acute mania in bipolar I disorder had a ≥ 50% reduction in
YMRS scores at week 3 of the study compared to the 44.1% in the control group (placebo). The
study revealed an RRR of 33.5% and an ARR of 14.8%.2 This indicates that patients taking
cariprazine had a 33.5% lower risk of developing acute mania and an absolute 14.8% decrease in
acute mania rates compared to the placebo. The NNT was calculated to be 7 (CI 95%), so for
every 7 patients taking cariprazine, 1 patient will have a >50% reduction in acute mania in
bipolar I disorder.2
In Durgam et al.3 there was a total of 238 patients enrolled in 29 study centers according
with the Good Clinical Practice guidelines. A total of 88 patients discontinued the study, the
majority being patients in the placebo group with insufficient therapeutic response (18) and those
in the treatment group with adverse events (17).3 Patients who were pregnant, had an additional
axis I disorder, had substance abuse, having their first manic episode, diagnosed with serious
medical condition (example cardiovascular), had a history of tardive dyskinesia, had neuroleptic
malignant syndrome, or were treated with a depot neuroleptic/ECT within the last 3 months were
excluded from the study.3 The study included a 3-week, double-blind evaluation of patients
randomized to either cariprazine 3-12 mg/day (based on tolerability) or placebo to treat acute
mania.3 The CER was calculated to be 29.5% for the control group and the EER was calculated
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to be 49% in the treatment group.3 This indicates that 49% of the patients receiving cariprazine
for treatment of acute mania in bipolar I disorder had a greater reduction in YMRS scores at
week 3 of the study compared to the 29.5% in the control group (placebo). The study revealed an
RRR of 66.1% and an ARR of 19.5%.3 This indicates that patients taking cariprazine had a
66.1% lower risk of developing acute mania and an absolute 19.5% decrease in acute mania rates
compared to the placebo. The NNT was calculated to be 5 (CI 95%), so for every 5 patients
taking cariprazine, 1 patient will have a greater reduction in acute mania in bipolar I disorder.3
Table 2: Treatment effects of cariprazine for acute mania in bipolar I disorder
Study
Calabrese
et al.1
Sachs et
al.2
Durgam et
al.3

P-value/CI
p<0.001/95%

CER
37.5%

EER
60.6%

RRR
61.6%

ARR
23.1%

NNT
5

p<0.01/95%

44.1%

58.9%

33.5%

14.8%

7

p<0.001/95%

29.5%

49.0%

66.1%

19.5%

5

In all three studies, cariprazine was generally safe and well-tolerated. In Calabrese et al.1
there were a total of 10 serious adverse events (SAEs), 3 being in the placebo group and 7 being
in the low dose cariprazine group. 7 of the 10 SAEs were associated with worsening mania and
there were no SAEs in the high dose cariprazine group.1 The most common (≥5% in any group)
treatment-emergent adverse events (TEAEs) in Calabrese et al.1 were akathisia, nausea,
constipation, and tremor (high dose cariprazine group only). There were no statistically
significant differences in change from baseline metabolic laboratory parameters or vital signs
between the treatment and placebo group.1
In Sachs et al.2 there were a total of 8 patients with SAEs, 3 being in the placebo group
and 5 being in the treatment group. The only SAE reported in more than one patient was
worsening of mania (1 in placebo and 2 in the treatment group).2 The only TEAEs that led to
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discontinuation were worsening of mania, akathisia, and rash (5/2, 0/5, and 2/0 for
placebo/treatment groups respectively).2 In Sachs et al.2 the mean changes in vital signs and
metabolic laboratory parameters were small and similar between groups.
In Durgam et al.3 there were a total of 10 SAEs, 6 being in the placebo group and 4 being
in the treatment group. The most common SAE was worsening of mania, which occurred in 6
patients (4 placebo and 2 treatment).3 The most common TEAEs (≥10% of treatment group)
were extrapyramidal disorder, headache, akathisia, constipation, nausea, and dyspepsia.3 Mean
changes in vital signs and metabolic laboratory parameters were small and similar between
groups with the exception of fasting glucose (increase with treatment group, p = 0.04).3 A
summary of calculated safety and tolerability for all three studies is demonstrated in Table 3.
Table 3: Safety and tolerability of oral cariprazine for acute mania in bipolar I disorder
Study

Calabrese et
al.1
Sachs et al.2
Durgam et
al.3

Control event
rate
(CER)
1.9%

Experimental
event rate
(EER)
4.2%

Relative risk
reduction
(RRR)
121.1%

Absolute risk
increase
(ARI)
2.3%

Number
needed to
harm (NNH)
44

1.3%
4.2%

0.60%
3.4%

-53.8%
-19.0%

-.70%
-.80%

-142.9%
-125.0%

Discussion
Cariprazine is a second generation antipsychotic medication that is a D2, D3, 5-HT1A
receptor partial agonist and a 5-HT2B receptor partial antagonist.2 It is mainly used to treat acute
mania in bipolar I disorder and schizophrenia, but has been used off-label to treat psychosis
associated with dementia.9 There is a black box warning however, that states cariprazine is not
approved for dementia related psychosis due to increased mortality with cardiovascular events.9
The only documented contraindication to cariprazine is hypersensitivity, although multiple
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cautions are issued including neuroleptic malignant syndrome history, seizure history,
cerebrovascular disease, cardiovascular disease, hypovolemia, dehydration, diabetes mellitus,
and leukopenia.9
These studies were limited by the lack of a competitive medication, short study duration,
and adequate measurement of remission rates for acute mania. Although there was significant
discontinuation among patients in all 3 studies, most were due to insufficient therapeutic
response or withdrawal of consent in the placebo group. Overall, TEAEs were generally mild
and similar side effects have been demonstrated in the second generation antipsychotic drug
class.
Conclusion
This review demonstrated that cariprazine is effective and safe in treating acute mania in
bipolar I disorder. Cariprazine was associated with a significantly greater reduction in acute
mania scores compared to placebo after three weeks of treatment in all studies reviewed. TEAEs
in all three studies were considered mild to moderate in intensity. The tolerability of cariprazine
was similar with minimal difference in laboratory parameters and vital signs between placebo
and treatment groups. Future studies are warranted to evaluate the long term outcomes of
treatment, competitive medication such as another antipsychotic, and accurate measurement of
remission rates. Studies conducted in the future should consider using a fixed dosing schedule to
improve efficacy and tolerability interpretations at specific doses of cariprazine. Cariprazine as a
second generation antipsychotic may continue to improve quality of life as a treatment option for
bipolar I disorder
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